\n\tWhat?<\/p>\n
\n\tBiotech company Impedimed<\/span> ((IPD<\/span>)) has surprised analysts and investors this morning by announcing FDA clearance of the Company’s LDex<\/span> U400<\/span> device. RBS<\/span> Morgans<\/span> analysts see "plenty of upside" for the share price following this announcement.<\/p>\n \n\tWhy?<\/p>\n \n\tImpedimed<\/span> has announced it has received clearance from the US FDA clearance of the Company’s LDex<\/span> U400<\/span> device to aid in the clinical assessment of unilateral lymphoedemaof<\/span> the arm in women, and legs for both men and women. Additionally, the FDA has allowed the indication to be expanded to include patients who will have, or who have had lymph nodes from the axillary<\/span> and pelvicregions<\/span> removed, damaged or irradiated. RBS<\/span> analysts, who have been positively surprised by this announcement, report this broadens the claim beyond just cancer and no longer links it to any one specific cancer.<\/p>\n \n\tThe analysts report company management sees this as an additional major expansion of the available market. RBS<\/span> estimates this could easily triple the current accessible market.<\/p>\n \n\tThe analysts point out their present forecasting does not include any upside for this approval. Previously the analysts have run scenarios which account for this possibility and it values the company over $4.00 per share. While admitting it is early days yet on penetrating this market, this morning's announcement is labelled<\/span> "very positive" by RBS<\/span> Morgans<\/span>.<\/p>\n \n\tRBS<\/span> anticipates investors will react positively to the announcement, while noting there's "plenty of upside to our price target and valuation".<\/p>\n \n\tThe FNArena<\/span> archive shows RBS<\/span> (Morgans<\/span>) rates the shares Buy with a price target of $1.14 (probably under review now). The shares last traded at $0.57.<\/p>\n \n\t <\/p>\n